



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Monday, November 23, 2009

## Daiichi Sankyo, Inc.

[View the current Daiichi Sankyo, Inc. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/29559-Daiichi+Sankyo%2C+Inc..html)

(<http://www.bioportfolio.com/biocorporate/29559-Daiichi+Sankyo%2C+Inc..html>)

### Contact Details:

**Two Hilton Court  
Parsippany  
New Jersey  
07054  
United States of America**

Tel: 973 359 2600  
Fax: 973 359 2645  
Email: [smallbusinessplan@daiichisankyo-us.com](mailto:smallbusinessplan@daiichisankyo-us.com)

Daiichi Sankyo Pharma Development is the product development arm of the U.S. organization, engaged in Clinical Development, Translational Medicine & Clinical Pharmacology, Regulatory Affairs & Risk Management, Informatics & Knowledge Management, Biostatistics and Data Operations and Development Research. We conduct clinical studies and expedite product registrations for the United States and Europe, and collaborate with our Tokyo parent company on all of our global product development projects as well. We are led by a group of highly experienced pharmaceutical executives who have gained broad experience at some of the world's leading pharmaceutical companies. In addition, we have a significant number of senior staff from Japan to assist in and coordinate our global development activities. Along with our staff of about 200 employees, we utilize outsourcing strategies for additional functional support. One such example is our partnership with MDS Pharma Services to establish the company's first collaborative clinical pharmacology unit. The unit is located in New Jersey and focuses on the evaluation of novel treatments for diabetes and lipid disorders.

Daiichi Sankyo, Inc. has just completed the integration of its two legacy companies that resulted in a new R&D organization -- including new processes and improved decision-making systems aimed at speeding global development.

### Press Releases on Daiichi Sankyo, Inc.:

[Reportlinker Adds  
Imaging Agents - A  
Worldwide Market  
Review](#)

20th November,  
2009 Reportlinker

*NEW YORK, Nov. 20 /PRNewswire/ --  
Reportlinker.com announces that a new  
market research report is available in its  
catalogue. Imaging Agents - A Worldwide  
Market Review <http://www.reportlinker.com>*

[New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient\(R\) for Patients with Acute Coronary Syndromes Managed with PCI](#)

18th November, 2009 Eli Lilly and Company

PARSIPPANY, N.J. and INDIANAPOLIS, Nov. 18 /PRNewswire-FirstCall/ -- Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one

[Reportlinker Adds Antibiotics - Global Trends](#)

18th November, 2009 Reportlinker

NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Antibiotics - Global Trends <http://www.reportlinker.com/p0164263>

[Reportlinker Adds Anticoagulants - A Global Market Review](#)

18th November, 2009 Reportlinker

NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Anticoagulants - A Global Market Review <http://www.reportlinker.com>

[American Heart Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular Disease Patients With Diabetes and Kidney Disease](#)

16th November, 2009 American Heart Association

Study highlights: - Risks of an anemia drug appear to outweigh its benefits among diabetic patients with kidney disease, anemia and a history of cardiovascular disease or stroke. - This first large,

## BioNews Results for Daiichi Sankyo, Inc.



- [Nuvo Research, Ranbaxy signs deal to market Oxoferin in Asian countries](#)  
*PharmaBiz: Nov 13 2009 12:12PM Matching: daiichi sankyo inc*
- [Exelixis Announces November 18 Webcast of Presentation at Business Wire via MSN Money: Nov 13 2009 1:44PM Matching: daiichi sankyo inc](#)
- [Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference](#)  
*Pharma Live: Nov 13 2009 9:38PM Matching: daiichi sankyo inc*
- [Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference](#)  
*Earthtimes.org: Nov 13 2009 2:02PM Matching: daiichi sankyo inc*
- [Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference](#)  
*Forbes.com: Nov 13 2009 1:46PM Matching: daiichi sankyo inc*

- [Exelixis Announces November 18 Webcast of Presentation at Lazards 6th Annual Healthcare Conference](#)  
*PR inside: Nov 13 2009 1:44PM Matching: daiichi sankyo inc*
- [Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference](#)  
*FinanzNachrichten.de: Nov 13 2009 1:41PM Matching: daiichi sankyo inc*
- [YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS](#)  
*CNW Telbec: Nov 12 2009 3:56AM Matching: daiichi sankyo inc*
- [Kaiser Permanente spinoff Archimedes offers health Rx](#)  
*Pacific Business News: Nov 12 2009 3:09AM Matching: daiichi sankyo inc*
- [Ligand Updates License Agreement with Exelixis](#)  
*SmartBrief: Nov 2 2009 7:59PM Matching: daiichi sankyo inc*
- [Ligand Updates License Agreement with Exelixis](#)  
*Pharma Live: Nov 2 2009 7:40PM Matching: daiichi sankyo inc*
- [Ligand Updates License Agreement with Exelixis](#)  
*FinanzNachrichten.de: Nov 2 2009 1:59PM Matching: daiichi sankyo inc*
- [Ligand Updates License Agreement with Exelixis](#)  
*Business Wire: Nov 2 2009 1:47PM Matching: daiichi sankyo inc*
- [Ligand Updates License Agreement with Exelixis](#)  
*Business Wire UK: Nov 2 2009 1:45PM Matching: daiichi sankyo inc*
- [FDA approves an expanded indication for BYETTA injection](#)  
*News-Medical.Net: Oct 31 2009 4:47AM Matching: daiichi sankyo inc*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

